Simulations Plus, Inc. (SLP)

NASDAQ: SLP · Real-Time Price · USD
16.93
-0.21 (-1.23%)
Jun 25, 2025, 4:00 PM - Market closed
-1.23%
Market Cap 340.48M
Revenue (ttm) 78.56M
Net Income (ttm) 7.26M
Shares Out 20.11M
EPS (ttm) 0.36
PE Ratio 47.01
Forward PE 37.14
Dividend $0.06 (0.35%)
Ex-Dividend Date Jul 29, 2024
Volume 505,862
Open 17.25
Previous Close 17.14
Day's Range 16.72 - 17.26
52-Week Range 16.72 - 49.72
Beta 0.97
Analysts Buy
Price Target 40.40 (+138.63%)
Earnings Date Jul 14, 2025

About SLP

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models,... [Read more]

Sector Healthcare
IPO Date Jun 18, 1997
Employees 247
Stock Exchange NASDAQ
Ticker Symbol SLP
Full Company Profile

Financial Performance

In 2024, Simulations Plus's revenue was $70.01 million, an increase of 17.52% compared to the previous year's $59.58 million. Earnings were $9.95 million, a decrease of -0.07%.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for SLP stock is "Buy." The 12-month stock price forecast is $40.4, which is an increase of 138.63% from the latest price.

Price Target
$40.4
(138.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Simulations Plus Announces Rescheduling of Third Quarter Fiscal 2025 Earnings Release and Conference Call

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled perf...

7 days ago - Business Wire

Simulations Plus: Further Downside Is Likely (Rating Downgrade)

Simulations Plus' Q3 FY25 results missed expectations, with revenue guidance cut sharply due to biopharma market weakness and services segment volatility. Organic growth continues to decelerate and th...

12 days ago - Seeking Alpha

Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt

Simulations Plus Inc SLP stock tanked after the company lowered its fiscal 2025 sales outlook.

13 days ago - Benzinga

Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...

13 days ago - Business Wire

Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled perf...

14 days ago - Business Wire

Simulations Plus Releases ADMET Predictor® 13

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

20 days ago - Business Wire

Simulations Plus Releases DILIsym® 11

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

5 weeks ago - Business Wire

Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

2 months ago - Business Wire

Simulations Plus: Benefiting From FDA Modernization And AI

Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, incl...

2 months ago - Seeking Alpha

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.

Other symbols: CERTCRL
2 months ago - Benzinga

Simulations Plus: I See Promising Growth, But I'm Staying Neutral

Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and p...

2 months ago - Seeking Alpha

Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript

Simulations Plus, Inc. (NASDAQ:SLP) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & CO...

2 months ago - Seeking Alpha

Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

2 months ago - Business Wire

Top 3 Health Care Stocks That Are Set To Fly This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: ARVNIOVA
3 months ago - Benzinga

Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...

3 months ago - Business Wire

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...

3 months ago - Business Wire

Simulations Plus to Participate in Upcoming Healthcare Investor Conferences

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance an...

5 months ago - Business Wire

Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements

RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and...

5 months ago - Business Wire

Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.

5 months ago - Business Wire

Simulations Plus Supported Development of Every FDA-Approved Drug in 2024

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approved by the U.S. FDA in 2024.

5 months ago - Business Wire

Simulations Plus, Inc. (SLP) Q1 2025 Earnings Call Transcript

Simulations Plus, Inc. (NASDAQ:SLP) Q1 2025 Earnings Conference Call January 7, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & ...

6 months ago - Seeking Alpha

Simulations Plus Reports First Quarter Fiscal 2025 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

6 months ago - Business Wire

Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions...

6 months ago - Business Wire

Simulations Plus to Participate in the BTIG Digital Health Forum

LANCASTER, Calif.--(BUSINESS WIRE)--CEO of Simulations Plus, Shawn O'Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on Monday, November 25, 2024.

Other symbols: ESG
7 months ago - Business Wire

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with the University of Connecticut, was awarded a new FDA grant to investigate additional LAI product technologies.

Other symbols: ESG
8 months ago - Business Wire